



## Regulatory Information

### **Procedures for Requesting or Viewing Proxy Information for the Combined Ordinary and Extraordinary Annual Meeting on May 5, 2011**

(Charenton-le-Pont, France – April 12, 2011 – 6:00 p.m.) – Shareholders are advised that the Combined Ordinary and Extraordinary Annual Meeting will be held on **Thursday, May 5, 2011 at 10:30 am CEST** at Palais des Congrès de Paris, 2 place de la Porte Maillot, 75017 Paris, France.

The Notice of Meeting, published in the Bulletin des Annonces Légales Obligatoires on March 23, 2011, contains information on the agenda, the proposed resolutions and the procedures for attending and voting.

Proxy information may be viewed in the Shareholders section of the Essilor website at [www.essilor.com](http://www.essilor.com) : 2011 Shareholders' Meeting.

As provided for in articles R.225-88 and R.225-89 of the French Commercial Code, any shareholder may consult the proxy documents and information, as described in article R.225-83 of the Commercial Code, at Company headquarters (147 rue de Paris, 94220 Charenton-le-Pont, France) or request that such documents be sent to him or her, by writing to Société Générale, Service des Assemblées, 32 rue du Champ de Tir, BP 81236 – 44312 Nantes Cedex 3.

*The world leader in ophthalmic optical products, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. The Company's mission is to enable everyone around the world to have good vision thanks to lenses that meet his or her unique vision requirements. Essilor allocates around 4% of annual revenues to research and development to continuously bring new, more effective products to market. Flagship brands include Varilux<sup>®</sup>, Crizal<sup>®</sup>, Definity<sup>®</sup>, Xperio<sup>®</sup>, Kodak<sup>®</sup> and Foster Grant<sup>®</sup>. Essilor also develops and markets equipment, instruments and services for eyecare professionals.*

*Essilor reported consolidated revenue of more than €3.9 billion in 2010 and employs 42,700 people. It operates 14 plants, 332 prescription laboratories and several research and development centers around the world and does business in around 100 countries.*

*For more information, please visit [www.essilor.com](http://www.essilor.com). The Essilor share trades on the NYSE Euronext Paris market and is included in the CAC 40 index.*

*Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.*

**Investor Relations and Financial Communications**

**Phone: +33 (0)1 49 77 42 16**